Logo image of LMND

LEMONADE INC (LMND) Stock Fundamental Analysis

NYSE:LMND - US52567D1072 - Common Stock

53.79 USD
+0.56 (+1.05%)
Last: 8/26/2025, 11:53:33 AM
Fundamental Rating

2

LMND gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 143 industry peers in the Insurance industry. LMND may be in some trouble as it scores bad on both profitability and health. LMND shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LMND has reported negative net income.
In the past year LMND has reported a negative cash flow from operations.
In the past 5 years LMND always reported negative net income.
In the past 5 years LMND always reported negative operating cash flow.
LMND Yearly Net Income VS EBIT VS OCF VS FCFLMND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

Looking at the Return On Assets, with a value of -10.54%, LMND is doing worse than 93.71% of the companies in the same industry.
LMND has a worse Return On Equity (-38.70%) than 91.61% of its industry peers.
Industry RankSector Rank
ROA -10.54%
ROE -38.7%
ROIC N/A
ROA(3y)-14.35%
ROA(5y)-14.76%
ROE(3y)-33.95%
ROE(5y)-29.77%
ROIC(3y)N/A
ROIC(5y)N/A
LMND Yearly ROA, ROE, ROICLMND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

LMND does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LMND Yearly Profit, Operating, Gross MarginsLMND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

LMND does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LMND has more shares outstanding
Compared to 5 years ago, LMND has more shares outstanding
Compared to 1 year ago, LMND has a worse debt to assets ratio.
LMND Yearly Shares OutstandingLMND Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
LMND Yearly Total Debt VS Total AssetsLMND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

LMND has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.23, LMND is in the better half of the industry, outperforming 65.73% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC8.89%
LMND Yearly LT Debt VS Equity VS FCFLMND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

LMND has a Current Ratio of 0.09. This is a bad value and indicates that LMND is not financially healthy enough and could expect problems in meeting its short term obligations.
LMND has a Current ratio of 0.09. This is in the better half of the industry: LMND outperforms 63.64% of its industry peers.
LMND has a Quick Ratio of 0.09. This is a bad value and indicates that LMND is not financially healthy enough and could expect problems in meeting its short term obligations.
LMND's Quick ratio of 0.09 is fine compared to the rest of the industry. LMND outperforms 63.64% of its industry peers.
Industry RankSector Rank
Current Ratio 0.09
Quick Ratio 0.09
LMND Yearly Current Assets VS Current LiabilitesLMND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 4.71% over the past year.
Looking at the last year, LMND shows a very strong growth in Revenue. The Revenue has grown by 27.51%.
LMND shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 50.90% yearly.
EPS 1Y (TTM)4.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.93%
Revenue 1Y (TTM)27.51%
Revenue growth 3Y60.06%
Revenue growth 5Y50.9%
Sales Q2Q%34.51%

3.2 Future

LMND is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.31% yearly.
Based on estimates for the next years, LMND will show a very strong growth in Revenue. The Revenue will grow by 36.86% on average per year.
EPS Next Y6.18%
EPS Next 2Y17.49%
EPS Next 3Y20.31%
EPS Next 5YN/A
Revenue Next Year35.42%
Revenue Next 2Y48.75%
Revenue Next 3Y45.54%
Revenue Next 5Y36.86%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
LMND Yearly Revenue VS EstimatesLMND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B
LMND Yearly EPS VS EstimatesLMND Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

LMND reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LMND. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LMND Price Earnings VS Forward Price EarningsLMND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 -30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LMND Per share dataLMND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

LMND's earnings are expected to grow with 20.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.49%
EPS Next 3Y20.31%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LMND!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEMONADE INC

NYSE:LMND (8/26/2025, 11:53:33 AM)

53.79

+0.56 (+1.05%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupInsurance
GICS IndustryInsurance
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)10-28 2025-10-28/amc
Inst Owners46.24%
Inst Owner Change2.66%
Ins Owners7.34%
Ins Owner Change-30.47%
Market Cap3.97B
Analysts47.14
Price Target46.03 (-14.43%)
Short Float %30.23%
Short Ratio5.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.32%
Min EPS beat(2)10.83%
Max EPS beat(2)25.8%
EPS beat(4)4
Avg EPS beat(4)19.38%
Min EPS beat(4)9.28%
Max EPS beat(4)31.6%
EPS beat(8)8
Avg EPS beat(8)17.27%
EPS beat(12)11
Avg EPS beat(12)15.43%
EPS beat(16)15
Avg EPS beat(16)14.74%
Revenue beat(2)2
Avg Revenue beat(2)1.2%
Min Revenue beat(2)0.32%
Max Revenue beat(2)2.09%
Revenue beat(4)4
Avg Revenue beat(4)1.69%
Min Revenue beat(4)0.32%
Max Revenue beat(4)3.68%
Revenue beat(8)7
Avg Revenue beat(8)1.98%
Revenue beat(12)11
Avg Revenue beat(12)4.15%
Revenue beat(16)15
Avg Revenue beat(16)3.75%
PT rev (1m)36.74%
PT rev (3m)49.7%
EPS NQ rev (1m)0.1%
EPS NQ rev (3m)3.9%
EPS NY rev (1m)5.1%
EPS NY rev (3m)5.72%
Revenue NQ rev (1m)2.06%
Revenue NQ rev (3m)7.63%
Revenue NY rev (1m)3.17%
Revenue NY rev (3m)6.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.62
P/FCF N/A
P/OCF N/A
P/B 7.54
P/tB 7.96
EV/EBITDA N/A
EPS(TTM)-2.83
EYN/A
EPS(NY)-1.77
Fwd EYN/A
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS8.13
BVpS7.13
TBVpS6.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.54%
ROE -38.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.35%
ROA(5y)-14.76%
ROE(3y)-33.95%
ROE(5y)-29.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 51.58%
Cap/Sales 1.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.09
Quick Ratio 0.09
Altman-Z N/A
F-Score4
WACC8.89%
ROIC/WACCN/A
Cap/Depr(3y)58.6%
Cap/Depr(5y)137.73%
Cap/Sales(3y)2.62%
Cap/Sales(5y)3.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.93%
EPS Next Y6.18%
EPS Next 2Y17.49%
EPS Next 3Y20.31%
EPS Next 5YN/A
Revenue 1Y (TTM)27.51%
Revenue growth 3Y60.06%
Revenue growth 5Y50.9%
Sales Q2Q%34.51%
Revenue Next Year35.42%
Revenue Next 2Y48.75%
Revenue Next 3Y45.54%
Revenue Next 5Y36.86%
EBIT growth 1Y-4.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.29%
EBIT Next 3Y28.47%
EBIT Next 5Y27.83%
FCF growth 1Y88.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y93.56%
OCF growth 3YN/A
OCF growth 5YN/A